]>Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation : Table 8
Table 8: Analyses of prognostic impact of quantitative and semiquantitative immunohistological estimates, as obtained from the pretreatment biopsies (number of patients analyzed shown in brackets).
S u r v i v a l a R e c u r r e n c e b
no pre-chemotherapy+pre-chemotherapyno pre-chemotherapy+pre-chemotherapy
P- v a l u e s c P- v a l u e s c
A n g i o g e n e s i s d .90.92.23.76
(65)(30)(65)(35)
Proliferation rate (%).56.52.82.54
(70)(46)(65)(42)
Proliferation index ( m m − 2 ).47.81.43.89
(70)(46)(65)(42)
p53 expression (%).18.29.43.11
(70)(46)(65)(42)
p53 index ( m m − 2 ).73.99.90.90
(70)(46)(65)(42)
MDR/Pgp.43.12.23.16
(70)(46)(65)(42)
a A nalysis based on disease-specific mortality, and for continuous parameters divided on the median, whereas for MDR/Pgp divided in a chemotherapy-sensitive group (score <2) and a chemotherapy-resistant group (score ≥2).
b A ll kinds of recurrences, but patients with persistent, progressive disease after primary therapy have been deleted from the analyses.
c 𝑃 -values as reported from log-rank tests.
d A ngiogenesis could not be estimated in 21 cases due to technical, immunohistological problems, see text.